# Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2018

- Company: [Can-Fite BioPharma Ltd.](/companies/canf.md) (CIK 1536196)
- Form: 20-F
- Filed: 2019-03-29
- Accepted by EDGAR: Mar 29, 2019, 16:28 ET
- Period: 2018-12-31
- Accession: 0001213900-19-005251
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1536196/000121390019005251/f20f2018_canfitebiopharma.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1536196/000121390019005251/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 12 months, 2018-01-01 to 2018-12-31 | $6.1m | us-gaap:ResearchAndDevelopmentExpense |
| Income tax | 12 months, 2018-01-01 to 2018-12-31 | $4.0k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Current assets | at 2018-12-31 | $7.9m | ifrs-full:CurrentAssets |
| Total assets | at 2018-12-31 | $8.0m | ifrs-full:Assets |
| Current liabilities | at 2018-12-31 | $3.1m | ifrs-full:CurrentLiabilities |
| Shares outstanding | at 2018-12-31 | 40,399,290 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1536196/000121390019005251/f20f2018_canfitebiopharma.htm

Filed Mar 29, 2019.
Source: SEC EDGAR, the filing index for accession 0001213900-19-005251. Last ingested by Listed: Nov 2, 2026, 07:04 ET. No prices; not investment advice.